Clinical Trials MS Treatment | Headache Treatment | Sleep Disorders Treatment | Memory Loss

Clinical Trials

We participate in clinical trials MS treatment, headache treatment, sleep disorders treatment, and memory loss. If there is a study that might be suitable for you, please get in touch with our research coordinators. Trials named are linked to clinicaltrials.gov
A complete description of clinical trials is available there, and from our research coordinators.

Send an e-mail to Leigh Kreshel.

Neurology: Current Clinical Trials Open For Enrollment

New Studies:

“Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA”

Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com

https://clinicaltrials.gov/ct2/show/NCT02348606?term=jazz&rank=15″


A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com

https://clinicaltrials.gov/ct2/show/study/NCT02284568?term=teva%2C+ppms&rank=1&show_locs=Y#locn


Phase 3 Study of RPC1063 in Relapsing MS

Clinical Coordinator – LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com

https://clinicaltrials.gov/ct2/show/study/NCT02294058?term=receptos&rank=1&show_locs=Y#locn


Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD

Clinical Coordinator – LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com

https://clinicaltrials.gov/ct2/show/NCT02073279?term=chugai&rank=1


MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

clinical Coordinator –LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com

http://www.clinicaltrial.gov/ct2/show/NCT01633112?term=CFTY720D2312&rank=1



A Clinical Evaluation Of The Safety Of Baclofen Er Capsules (Grs) When Administered Once Daily To Subjects With Spasticity Due To Multiple Sclerosis (MS): An Open Label, Long Term, Safety Trial

Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com

http://http://www.clinicaltrial.gov/ct2/show/NCT01797185?term=CLR_09_21&rank=1



Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis)

Clinical Coordinator – Leigh Kreshel, MS, CCRC
Phone: 913-827-4262, Email: lkreshel@neurokc.com

http://www.clinicaltrial.gov/ct2/show/NCT01457352?term=CLR_09_21&rank=2


Action of Baclofen Capsules in Spasticity Due to Multiple Sclerosis

Clinical Coordinator – Shannon Cone, LPN, CCRC
Phone: 913-827-4260, Email: scone@neurokc.com

For more information, please use the link below:

http://www.clinicaltrial.gov/ct2/show/NCT02027025?term=CLR_11_03&rank=1


Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Clinical Coordinator – LeAnn Cannon, LPN, CCRC
Phone: 913-827-4261, Email: lcannon@neurokc.com

http://www.clinicaltrial.gov/ct2/show/NCT01442194?term=Novartis+Passage&rank=1


Dimethyl Fumarate (DMF) Observational Study

Clinical Coordinator – Shannon Cone, LPN, CCRC
Phone: 913-827-4260, Email: scone@neurokc.com

http://www.clinicaltrial.gov/ct2/show/NCT02047097?term=tecfidera%2C+Esteem&rank=1

Enjoy the article? Share the link: